Table 1 Patient characteristics and treatment responses.
Specimen No. | Diagnosis | Age and Sex | Initial stage | Specimen site | Genomic findings | Treatment and response prior dissection ( < 2 years) | Treatment and response post dissection ( < 2 years) |
|---|---|---|---|---|---|---|---|
1 | Pancreatic adenocarcinoma | 55/Male | IV | Secondary–peritoneum | BRCA2, KRAS, MTAP, CDKN2A/B | – | 1. Short term partial remission with Folinic acid, 5-FU, Irinotecan and Oxaliplatin. 2. Stable disease with Pembrolizumab and Lenvatinib. |
2 | Desmoplastic small round cell tumor of the peritoneum | 27/Male | IV | Secondary–peritoneum | No alterations detected | – | 1. Stable disease with Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide and Etoposide. 2. Stable disease with Irinotecan and temozolomide. 3. Deterioration with Pemmbrolizumab. 4. Stable disease with Cyclophosphamide and Topotecan. |
3 | Primary peritoneal carcinoma | 67/Female | IV | Primary | TP53, PIK3CA, MET, BRCA2, uncertain significance, ER + , PR+ | 1. Partial remission with Paclitaxel and Carboplatin. 2. Short term stable disease with Bevacizumab and Doxil. 3. No response with Olaparib. | Deterioration with Topotecan Deceased |
4 | Moderately differentiated adenocarcinoma of large intestine | 70/Male | IV | Secondary– liver | TP53, KRAS, PIK3K, SMAD4 | Partial response with Folinic acid, 5-FU and Oxaliplatin. | – Deceased (not cancer related) |
5 | Pancreatic adenocarcinoma | 71/Male | III | Primary | TP53, KRAS, PIK3K, SMAD4 | – | – Deceased |
6 | Mucinous carcinoma of appendix | 65/Female | IV | Secondary– peritoneum | ATM | – | 1. Stable disease with Oxaliplatin and 5-FU. 2. Stable disease with Bevacizumab and 5-FU. Deceased |
7 | Squamous cell carcinoma of the anal canal | 70/Male | IV | Secondary– liver | KRAS, SMAD4, PIK3CA, MYC, BRCA1, EZH2, FABP5, PARP1, TOPOIIa, BIRC5 | 1. Partial remission with Cisplatin and 5-FU. 2. Stable disease with Nivolumab. 3. No response with Paclitaxel. | 1. Partial remission with Paclitaxel. 2. Deterioration with Mitomycin. |
8 | Pancreatic adenocarcinoma | 44/Male | III | Primary | TP53, BRCA2, KRAS, CDKN2A/B | Stable disease with Folinic acid, 5-FU, Irinotecan and Oxaliplatin. | Partial response with Gemcitabine and Cisplatin. |
9 | Pancreatic neuroendocrine adenocarcinoma | 56/Male | III | Primary | – | – | Somatostatin Cancer free |
10 | Adenocarcinoma of the colon | 53/Female | IV | Secondary–peritoneum | TP53, HER2+, APC | – | 1. Remission with Oxaliplatin, Capecitabine and Herceptin. 2. Remission with Herceptin. |
